What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines

被引:72
作者
Burdin, Nicolas [1 ]
Handy, Lori Kestenbaum [2 ]
Plotkin, Stanley A. [3 ]
机构
[1] Sanofi Pasteur, EU Res & Non Clin Safety, R&D, Campus Merieux, F-69280 Marcy Letoile, France
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Nemours Alfred I duPont Hosp Children, Div Infect Dis,Pediat, Wilmington, DE 19803 USA
[3] Univ Penn, Pediat, Vaxconsult, Doylestown, PA 18902 USA
关键词
ADENYLATE-CYCLASE TOXIN; CELL-MEDIATED-IMMUNITY; MEMORY B-CELL; CPG-CONTAINING OLIGODEOXYNUCLEOTIDE; CHILDREN; 5; YEARS; WHOLE-CELL; BORDETELLA-PERTUSSIS; PROTECTIVE IMMUNITY; ACELLULAR VACCINE; T-CELLS;
D O I
10.1101/cshperspect.a029454
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pertussis is resurgent in some countries, particularly those in which children receive acellular pertussis (aP) vaccines in early infancy and boosters later in life. Immunologic studies show that, whereas whole-cell pertussis (wP) vaccines orient the immune system toward Th1/Th17 responses, acellular pertussis vaccines orient toward Th1/Th2 responses. Although aP vaccines do provide protection during the first years of life, the change in T-cell priming results in waning effectiveness of aP as early as 2-3 years post-boosters. Although other factors, such as increased virulence of pertussis strains, better diagnosis, and better surveillance may play a role, the increase in pertussis appears to be the result of waning immunity. In addition, studies in baboon models, requiring confirmation in humans, show that aP is less able to prevent nasopharyngeal colonization of Bordetella pertussis than wP or natural infection.
引用
收藏
页数:18
相关论文
共 144 条
[1]  
Acosta AM, 2015, PEDIATRICS, V135, P981, DOI [10.1542/peds.2014-4118, 10.1542/peds.2014-3358]
[2]   Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity [J].
Allen, Aideen C. ;
Mills, Kingston H. G. .
EXPERT REVIEW OF VACCINES, 2014, 13 (10) :1253-1264
[3]   Asymptomatic transmission and the resurgence of Bordetella pertussis [J].
Althouse, Benjamin M. ;
Scarpino, Samuel V. .
BMC MEDICINE, 2015, 13
[4]   Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate [J].
Asensio, Cristian J. A. ;
Emilia Gaillard, Maria ;
Moreno, Griselda ;
Bottero, Daniela ;
Zurita, Eugenia ;
Rumbo, Martin ;
van der Ley, Peter ;
van der Ark, Arno ;
Hozbor, Daniela .
VACCINE, 2011, 29 (08) :1649-1656
[5]   A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis [J].
Asokanathan, Catpagavalli ;
Corbel, Michael ;
Xing, Dorothy .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (02) :325-331
[6]   Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine [J].
Ausiello, CM ;
Lande, R ;
Urbani, F ;
Di Carlo, B ;
Stefanelli, P ;
Salmaso, S ;
Mastrantonio, P ;
Cassone, A .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1989-1995
[7]   Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines [J].
Ausiello, CM ;
Urbani, F ;
laSala, A ;
Lande, R ;
Cassone, A .
INFECTION AND IMMUNITY, 1997, 65 (06) :2168-2174
[8]   Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood [J].
Bancroft, Tara ;
Dillon, Myles B. C. ;
Antunes, Ricardo da Silva ;
Paul, Sinu ;
Peters, Bjoern ;
Crotty, Shane ;
Arlehamn, Cecilia S. Lindestam ;
Sette, Alessandro .
CELLULAR IMMUNOLOGY, 2016, 304 :35-43
[9]   Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection [J].
Barkoff, Alex-Mikael ;
Grondahl-Yli-Hannuksela, Kirsi ;
Vuononvirta, Juho ;
Mertsola, Jussi ;
Kallonen, Teemu ;
He, Qiushui .
VACCINE, 2012, 30 (48) :6897-6902
[10]   Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine [J].
Barreto, L. ;
Guasparini, R. ;
Meekison, W. ;
Noya, F. ;
Young, L. ;
Mills, E. .
VACCINE, 2007, 25 (48) :8172-8179